Synapse - Works

Results (1109)

A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML

Journal Article

Dao, T.; Xiong, G.; Mun, S. S.; Meyerberg, J.; Korontsvit, T.; Xiang, J.; Cui, Z.; Chang, A. Y.; Jarvis, C.; Cai, W.; more...
Blood (2024)

Fulltext@MSK | Save

Ibrutinib-based therapy reinvigorates CD8(+) T cells compared to chemoimmunotherapy: Immune monitoring from the E1912 trial

Journal Article

Papazoglou, D.; Wang, X. V.; Shanafelt, T. D.; Lesnick, C. E.; Ioannou, N.; De Rossi, G.; Herter, S.; Bacac, M.; Klein, C.; Tallman, M. S.; more...
Blood (2024)

Fulltext@MSK | Save

Obecabtagene autoleucel (obe-cel, AUTO1) for relapsed/refractory adult B-cell acute lymphoblastic leukemia (R/R B-ALL): Pooled analysis of the ongoing FELIX phase Ib/II study

Meeting Abstract

Roddie, C.; Sandhu, K. S.; Tholouli, E.; Shaughnessy, P.; Barba, P.; Guerreiro, M.; Bishop, M. R.; Yared, J. A.; Ghobadi, A.; Yallop, D.; more...
Blood (2023)

Fulltext@MSK | Save

Pelabresib in combination with ruxolitinib for Janus Kinase inhibitor treatment-naïve patients with myelofibrosis: Results of the MANIFEST-2 randomized, double-blind, phase 3 study

Meeting Abstract

Rampal, R. K.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; more...
Blood (2023)

Fulltext@MSK | Save

Molecular taxonomy of myelodysplastic syndromes and its clinical implications

Meeting Abstract

Bernard, E.; Hasserjian, R.; Greenberg, P. L.; Ossa, J. E. A.; Creignou, M.; Nannya, Y.; Tuechler, H.; Medina-Martínez, J. S.; Levine, M. F.; Jädersten, M.; more...
Blood (2023)

Fulltext@MSK | Save

Long-term efficacy and safety of obecabtagene autoleucel (obe-cel) in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia ([R/R B-ALL]; Pooled analysis from ALLCAR19 and FELIX phase Ib studies) or other B-cell malignancies (ALLCAR19 extension study)

Meeting Abstract

Roddie, C.; Tholouli, E.; Shaughnessy, P.; Jabbour, E.; Logan, A. C.; Hodby, K.; Mountjoy, L.; Bloor, A. J. C.; Irvine, D.; Linch, D. C.; more...
Blood (2023)

Fulltext@MSK | Save

Long-term follow up for SWOG 1318: Combination of dasatinib, prednisone, and blinatumomab for older patients with philadelphia-chromosome (Ph) positive acute lymphoblastic leukemia (ALL)

Meeting Abstract

Advani, A. S.; Moseley, A. B.; O'Dwyer, K. M.; Wood, B. L.; Park, J. H.; Wieduwilt, M. J.; Jeyakumar, D.; Yaghmour, G.; Atallah, E. L.; Gerds, A. T.; more...
Blood (2023)

Fulltext@MSK | Save

Phase 1/2 study of TP-3654, a selective PIM1 kinase inhibitor: Preliminary data showed clinical activity and cytokine reductions in relapsed/refractory myelofibrosis patients

Meeting Abstract

Rein, L. A. M.; El Chaer, F.; Yuda, J.; Shimoda, K.; McCloskey, J.; Takami, A.; Haque, T.; Ichii, M.; Shirane, S.; Fukaya, M.; more...
Blood (2023)

Fulltext@MSK | Save

Validation of the composite complete response (cCR) definitions in the International Working Group (IWG) 2023 criteria in patients (pts) with higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) treated with hypomethylating agents (HMA) - A large, multicenter, retrospective analysis from the validate database

Meeting Abstract

Bewersdof, J. P.; Kewan, T.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; Carraway, H. E.; Desai, P.; more...
Blood (2023)

Fulltext@MSK | Save

With up to 8 years of therapy, asciminib (ASC) monotherapy demonstrated continued favorable efficacy, safety, and tolerability in patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) without the T315I mutation: Final results from the phase 1 x2101 study

Meeting Abstract

Hochhaus, A.; Kim, D. W.; Cortes, J.; Sasaki, K.; Mauro, M.; Hughes, T. P.; Breccia, M.; Talpaz, M.; Minami, H.; Goh, Y. T.; more...
Blood (2023)

Fulltext@MSK | Save